Department of Molecular Biology and Genetics2024-11-0920160959-804910.1016/S0959-8049(16)32835-0http://dx.doi.org/10.1016/S0959-8049(16)32835-0https://hdl.handle.net/20.500.14288/8819Background: Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has tremendous promise in treating various forms of cancers. However, many cancer cells exhibit or develop resistance to TRAIL. Interestingly, many studies have identified several secondary agents that can overcome TRAIL resistance. To expand on these studies, we conducted an extensive drug-re-profiling screen to identify FDA-approved compounds that can be used clinically as TRAIL-sensitizing agents in a very malignant type of brain cancer, glioblastoma multiforme (GBM). Material and Methods: GBM cell lines U87MG, U373 and non-malignant cell lines BJ fibroblasts and Normal Human Astrocytes were used in in vitro experiments. 1,200 FDA approved drugs containing library was screened as single agents (5 uM) and/or TRAIL (25 ng/ml) in U87MG and U87MGR50. Cell viability was detected by an ATP-based assay after 24−48 hours. Chosen lead, Mitoxantrone was further studied by cell viability assays, proliferation by live cell imaging, apoptotic gene expression levels by qRT-PCR and death receptor and apoptotic protein expression levels by Western Blot. Results: Using selected isogenic GBM cell pairs with differential levels of TRAIL sensitivity, we revealed 26 TRAIL-sensitizing compounds, 13 of which were effective as single agents. Cardiac glycosides constituted a large group of TRAIL-sensitizing compounds, and they were also effective on GBM cells as single agents. We then explored a second class of TRAIL-sensitizing drugs, which were enhancers of TRAIL response without any effect on their own. One such drug, Mitoxantrone, a DNA-damaging agent, did not cause toxicity to non-malignant cells at the doses that synergized with TRAIL on tumor cells. We investigated the downstream changes in apoptosis pathway components upon Mitoxantrone treatment, and observed that Death Receptors (DR4 and DR5) expression was upregulated, and pro-apoptotic and anti-apoptotic gene expression patterns were altered in favor of apoptosis. Conclusions: Together, our results suggest that combination of Mitoxantrone and TRAIL can be a promising therapeutic approach for GBM patients.OncologyMeeting Abstract1879-0852390503500230Q17465